CytoSorbents raises $1.6M from Series A warrant exercises; total rights offering proceeds $7.85M

Cytosorbents Corp

1,417,208 Series A Right Warrants exercised at $1.13 each for $1.6M gross proceeds upon expiration.
Total rights offering gross proceeds reached $7.85M; net liquidity increased by ~$12.3M after restricted cash released.
Approximately 4.8M shares remain reserved for Series B Right Warrants, exercisable until April 10, 2025.
CEO notes progress on DrugSorb-ATR regulatory applications with U.S. FDA and Health Canada, expecting decisions in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.